These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 9677174

  • 1. Lack of pharmacokinetic interaction between nelfinavir and nevirapine.
    Skowron G, Leoung G, Kerr B, Dusek A, Anderson R, Beebe S, Grosso R.
    AIDS; 1998 Jul 09; 12(10):1243-4. PubMed ID: 9677174
    [No Abstract] [Full Text] [Related]

  • 2. Nelfinavir and nevirapine interaction?
    Mulcahy F, Barry M, Merry C, Back D.
    AIDS; 1998 Dec 03; 12(17):2361. PubMed ID: 9863887
    [No Abstract] [Full Text] [Related]

  • 3. dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
    Skowron G.
    Antivir Ther; 1998 Dec 03; 3 Suppl 4():61-2. PubMed ID: 10723513
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis.
    Taylor S, Little J, Halifax K, Drake S, Back D.
    J Antimicrob Chemother; 2000 May 03; 45(5):716-7. PubMed ID: 10797104
    [No Abstract] [Full Text] [Related]

  • 5. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
    Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ.
    Drug Metab Dispos; 2001 Feb 03; 29(2):100-2. PubMed ID: 11159797
    [Abstract] [Full Text] [Related]

  • 6. Interactions between recreational drugs and antiretroviral agents.
    Antoniou T, Tseng AL.
    Ann Pharmacother; 2002 Oct 03; 36(10):1598-613. PubMed ID: 12243611
    [Abstract] [Full Text] [Related]

  • 7. Pharmacology of antiretroviral drugs.
    Hoetelmans RM.
    Antivir Ther; 1999 Oct 03; 4 Suppl 3():29-41. PubMed ID: 16021869
    [Abstract] [Full Text] [Related]

  • 8. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
    Shiraki N, Hamada A, Yasuda K, Fujii J, Arimori K, Nakano M.
    Biol Pharm Bull; 2000 Dec 03; 23(12):1528-31. PubMed ID: 11145192
    [Abstract] [Full Text] [Related]

  • 9. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M, Salzberger B, Stiepel A, Hoetelmans R, Diehl V, Fätkenheuer G.
    Eur J Med Res; 1999 Feb 25; 4(2):54-8. PubMed ID: 10066640
    [Abstract] [Full Text] [Related]

  • 10. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease.
    Maserati R, Villani P, Seminari E, Pan A, Lo Caputo S, Regazzi MB.
    AIDS; 1999 May 07; 13(7):870-1. PubMed ID: 10357395
    [No Abstract] [Full Text] [Related]

  • 11. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.
    Merry C, Barry MG, Mulcahy F, Ryan M, Tjia JF, Halifax KL, Breckenridge AM, Back DJ.
    AIDS; 1998 Jul 09; 12(10):1163-7. PubMed ID: 9677165
    [Abstract] [Full Text] [Related]

  • 12. Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments.
    Russo G, Paganotti GM, Soeria-Atmadja S, Haverkamp M, Ramogola-Masire D, Vullo V, Gustafsson LL.
    Infect Genet Evol; 2016 Jan 09; 37():192-207. PubMed ID: 26602158
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency.
    Izzedine H, Diquet B, Launay-Vacher V, Jouan M, Theou N, Deray G.
    AIDS; 1999 Oct 01; 13(14):1989. PubMed ID: 10513666
    [No Abstract] [Full Text] [Related]

  • 14. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
    Kaldor SW, Kalish VJ, Davies JF, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH.
    J Med Chem; 1997 Nov 21; 40(24):3979-85. PubMed ID: 9397180
    [Abstract] [Full Text] [Related]

  • 15. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.
    Cohn SE, Park JG, Watts DH, Stek A, Hitti J, Clax PA, Yu S, Lertora JJ, ACTG A5093 Protocol Team.
    Clin Pharmacol Ther; 2007 Feb 21; 81(2):222-7. PubMed ID: 17192768
    [Abstract] [Full Text] [Related]

  • 16. Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
    Gonzalez A, Everall IP.
    AIDS; 1998 Dec 24; 12(18):2365-7. PubMed ID: 9875573
    [No Abstract] [Full Text] [Related]

  • 17. [New combination medications].
    Agosto M.
    Sidahora; 1997 Dec 24; ():43-6. PubMed ID: 11364501
    [Abstract] [Full Text] [Related]

  • 18. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
    Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, Dusek A.
    J Infect Dis; 1999 May 24; 179(5):1116-23. PubMed ID: 10191212
    [Abstract] [Full Text] [Related]

  • 19. Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.
    Boffito M, Pozniak A, Kearney BP, Higgs C, Mathias A, Zhong L, Shah J.
    Antimicrob Agents Chemother; 2005 Oct 24; 49(10):4386-9. PubMed ID: 16189129
    [Abstract] [Full Text] [Related]

  • 20. [Etravirine drug interactions].
    Pérez VE, Sánchez-Parra C, Serrano Villar S.
    Enferm Infecc Microbiol Clin; 2009 Dec 24; 27 Suppl 2():27-31. PubMed ID: 20116625
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.